In humans, copeptin (the stable vasopressin analogue) concentrations in plasma have been found to be significantly associated with increased risk of type two diabetes, chronic kidney disease, and cardiovascular disease [66,67,68,69]. Here, AVP is linked to chronic kidney disease.